The anti-VEGF antibody, bevacizumab, was as effective as GnRH agonists in the regression of endometriotic lesions in a rat endometriosis model, and significantly inhibited cell proliferation in lesions, reduced vascular density, increased the proportion of apoptotic cells, and reduced VEGF levels in the peritoneal fluid of female BALB/c mice [37–39]. This evidence concerns the gene GNRH1 and endometriosis.